GUARDANT HEALTH INC. and Northewestern University have entered into a comprehensive partnership that will make Guardant360 the preferred liquid biopsy test for patients with advanced cancer treated at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. The agreement also covers multiple large-scale prospective clinical trials that will apply Guardant Health’s technology to a...
The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.
